Trial site
Rhode Island Mood & Memory Research Institute
- 4running trials
- 10closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease13 trials
- Frontotemporal dementia1 trial
- Mild cognitive impairment1 trial
- Phase
- Phase 312 trials
- Phase 22 trials
- Status
- Completed5 trials
- Terminated5 trials
- Active, not recruiting3 trials
- Recruiting1 trial
- Lead sponsor
- Eli Lilly and Company5 trials
- Alzheon Inc.2 trials
- Biogen2 trials
- Cassava Sciences, Inc.2 trials
- Bristol-Myers Squibb1 trial
- and 2 more
Running trials
Recruiting
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Active, not recruiting
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease1 recruiting
Closed trials
Completed
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Terminated
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Completed
Completed
Completed
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Terminated
Terminated
Site data: ClinicalTrials.govUpdated 18 Nov 2026